Recent Developments and Challenges in Molecular-Targeted Therapy of Non-Small-Cell Lung Cancer.

Rohilla, S; Singh, M; Alzarea, SI; Almalki, WH; Al-Abbasi, FA; Kazmi, I; Afzal, O; Altamimi, ASA; Singh, SK; Chellappan, DK; Dua, K; Gupta, G

Recent Developments and Challenges in Molecular-Targeted Therapy of Non-Small-Cell Lung Cancer.

Rohilla, S Singh, M Alzarea, SI Almalki, WH Al-Abbasi, FA Kazmi, I Afzal, O Altamimi, ASA Singh, SK Chellappan, DK Dua, K

Gupta, G

Permalink

Publisher:: Begell House
Publication Type:: Journal Article
Citation:: J Environ Pathol Toxicol Oncol, 2023, 42, (1), pp. 27-50
Issue Date:: 2023

Closed Access

	Filename	Description	Size
	21974873_12718785780005671.pdf	Published version	7.84 MB	Adobe PDF	View/Open

Copyright Clearance Process

Recently Added
In Progress
Closed Access

This item is closed access and not available.

Full metadata record

Field	Value	Language
dc.contributor.author	Rohilla, S
dc.contributor.author	Singh, M
dc.contributor.author	Alzarea, SI
dc.contributor.author	Almalki, WH
dc.contributor.author	Al-Abbasi, FA
dc.contributor.author	Kazmi, I
dc.contributor.author	Afzal, O
dc.contributor.author	Altamimi, ASA
dc.contributor.author	Singh, SK
dc.contributor.author	Chellappan, DK
dc.contributor.author	Dua, K https://orcid.org/0000-0002-7507-1159
dc.contributor.author	Gupta, G
dc.date.accessioned	2024-02-02T00:13:44Z
dc.date.available	2024-02-02T00:13:44Z
dc.date.issued	2023
dc.identifier.citation	J Environ Pathol Toxicol Oncol, 2023, 42, (1), pp. 27-50
dc.identifier.issn	0731-8898
dc.identifier.issn	2162-6537
dc.identifier.uri	http://hdl.handle.net/10453/175259
dc.description.abstract	Treatment of lung cancer with conventional therapies, which include radiation, surgery, and chemotherapy results in multiple undesirable adverse or side effects. The major clinical challenge in developing new drug therapies for lung cancer is resistance, which involves mutations and disturbance in various signaling pathways. Molecular abnormalities related to epidermal growth factor receptor (EGFR), v-Raf murine sarcoma viral oncogene homolog B1 (B-RAF) Kirsten rat sarcoma virus (KRAS) mutations, translocation of the anaplastic lymphoma kinase (ALK) gene, mesenchymal-epithelial transition factor (MET) amplification have been studied to overcome the resistance and to develop new therapies for non-small cell lung cancer (NSCLC). But, inevitable development of resistance presents limits the clinical benefits of various new drugs. Here, we review current progress in the development of molecularly targeted therapies, concerning six clinical biomarkers: EGFR, ALK, MET, ROS-1, KRAS, and B-RAF for NSCLC treatment.
dc.format	Print
dc.language	eng
dc.publisher	Begell House
dc.relation.ispartof	J Environ Pathol Toxicol Oncol
dc.relation.isbasedon	10.1615/JEnvironPatholToxicolOncol.2022042983
dc.rights	info:eu-repo/semantics/closedAccess
dc.subject.classification	Oncology & Carcinogenesis
dc.subject.classification	3211 Oncology and carcinogenesis
dc.subject.classification	3214 Pharmacology and pharmaceutical sciences
dc.subject.mesh	Animals
dc.subject.mesh	Mice
dc.subject.mesh	Carcinoma, Non-Small-Cell Lung
dc.subject.mesh	Lung Neoplasms
dc.subject.mesh	Molecular Targeted Therapy
dc.subject.mesh	Proto-Oncogene Proteins p21(ras)
dc.subject.mesh	ErbB Receptors
dc.subject.mesh	Mutation
dc.subject.mesh	Animals
dc.subject.mesh	Mice
dc.subject.mesh	Carcinoma, Non-Small-Cell Lung
dc.subject.mesh	Lung Neoplasms
dc.subject.mesh	Mutation
dc.subject.mesh	Proto-Oncogene Proteins p21(ras)
dc.subject.mesh	Molecular Targeted Therapy
dc.subject.mesh	ErbB Receptors
dc.subject.mesh	Animals
dc.subject.mesh	Mice
dc.subject.mesh	Carcinoma, Non-Small-Cell Lung
dc.subject.mesh	Lung Neoplasms
dc.subject.mesh	Molecular Targeted Therapy
dc.subject.mesh	Proto-Oncogene Proteins p21(ras)
dc.subject.mesh	ErbB Receptors
dc.subject.mesh	Mutation
dc.title	Recent Developments and Challenges in Molecular-Targeted Therapy of Non-Small-Cell Lung Cancer.
dc.type	Journal Article
utslib.citation.volume	42
utslib.location.activity	United States
pubs.organisational-group	University of Technology Sydney
pubs.organisational-group	University of Technology Sydney/Faculty of Health
pubs.organisational-group	University of Technology Sydney/Faculty of Health/Public Health
utslib.copyright.status	closed_access	*
dc.date.updated	2024-02-02T00:13:42Z
pubs.issue	1
pubs.publication-status	Published
pubs.volume	42
utslib.citation.issue	1

Abstract:

Treatment of lung cancer with conventional therapies, which include radiation, surgery, and chemotherapy results in multiple undesirable adverse or side effects. The major clinical challenge in developing new drug therapies for lung cancer is resistance, which involves mutations and disturbance in various signaling pathways. Molecular abnormalities related to epidermal growth factor receptor (EGFR), v-Raf murine sarcoma viral oncogene homolog B1 (B-RAF) Kirsten rat sarcoma virus (KRAS) mutations, translocation of the anaplastic lymphoma kinase (ALK) gene, mesenchymal-epithelial transition factor (MET) amplification have been studied to overcome the resistance and to develop new therapies for non-small cell lung cancer (NSCLC). But, inevitable development of resistance presents limits the clinical benefits of various new drugs. Here, we review current progress in the development of molecularly targeted therapies, concerning six clinical biomarkers: EGFR, ALK, MET, ROS-1, KRAS, and B-RAF for NSCLC treatment.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/175259